Loading company…
Busan-based SillaJen develops oncolytic immunotherapy treatments, led by its Pexa-Vec (JX-594) candidate.
Founded in 2006 in Busan, South Korea, SillaJen develops oncolytic immunotherapy for cancer treatment, with its main product Pexa-Vec (JX-594). The company is running clinical trials, including the PHOCUS trial in China for liver cancer and a renal cell carcinoma trial with Regeneron's Cemiplimab. Its CEO is Kim Kyung. In December 2012, it raised KRW 150 billion in an IPO, and its Pre-IPO round raised KRW 40,000 mn from investors including Hana Securities and LINEA Investment.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in